Replies to post #485938 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

In another embodiment the immature dendritic cells are induced to begin maturation with a dendritic cell maturation agent, for example, heat inactivated BCG, in combination with IFNy. Prior to full and complete maturation, the maturing dendritic cells are isolated and formulated for administration to an individual. The formulation can comprise the inflammation-activating lipid or the inflammation-activating lipid can be a separate composition that is co- administered with the composition comprising the maturing dendritic cells. The composition comprising the inflammation-activating lipid can be administered before, concurrently, or subsequent to the administration of the maturing dendritic cells. In this embodiment, the inflammation- activating lipid is acting as an adjuvant to the maturing dendritic cells subsequent to their administration to an individual. The antigen is taken up by the activated maturing dendritic cells in vivo or ex vivo subsequent to administration and processed for presentation to T cells in the body of the individual. As above, the activated maturing dendritic cells and the inflammation activating lipid can be administered into a tumor, a tumor bed or a tissue area surrounding a tumor in an individual in need of such treatment.

[biosectinvestor]

The other thing I like about their patents is the source for the dendritic cells is generally not limited to any particular sourcing, i.e. autologous. The patents are quite broad. With acquisitions they might even expand to other kinds of sources including deals with companies that engineer such cell types from IPS cells. There are very many directions in which these patents can go.